

<b>FORM PTO-1449</b> <b>(R v. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)	<b>Atty. Docket No.</b>  98,164-H23	<b>Serial No.</b>  To Be Assigned
	<b>Applicant:</b>  Wolff, et al.	
	<b>Filing Date:</b>  Concurrently Herewith	<b>Group:</b>


#### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate
KG	5,209,933	5/11/93	MacFarlane et al.			
	4,567,264	1/28/96	Kluge et al.			
	5,472,707	12/5/95	Samuels et al.			
	5,506,229	4/9/96	Dow et al.			
KG	5,670,171	9/23/97	Santus et al.			

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
KG	WO 94/26266	11/24/94					



#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KG		Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99:5-6, 1990.
KG		Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect of ischaemic myocardium. Eur J Clin Pharmacol 38:111-114, 1990.
EXAMINER		DATE CONSIDERED
		11/22/97

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Dock t No.</b>  98,164-H23	<b>Serial No.</b>  To Be Assigned
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b>  Wolff et al.	
		<b>Filing Date:</b>  Concurrently Herewith	<b>Group:</b>

### ABSTRACTS


KG	Ferrandon, P et al. Ranolazine but not allopurinol or dipyridamole reduces the ventricular acidosis and lactate produced by low perfusion flow in isolated rat hearts. Therapie 45:10, 1990
	Cocco G, Rousseau MF, Bouvy T, Cheron P, William C, Detry JM, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina petoris. Eur Heart J 13(Supp):97, 1992
	Rousseau MF, Cocco G, Bouvy T, Cheron P, William GJ, Detry JMR, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina petoris. Circulation 86(Supp I):2843, 1992.
	Rousseau MF, Van Eyll C, Van Mechelen H, Harlow BJ, Pouleur H. Novel metabolic ranolazine selectively improves diastolic function in heart failure. Circulation 86(Supp):375, 1992.
	Collins-Nakai RL, Barr R, Humen D, Lopaschuk GD. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Can J Cardiol 9(Supp E):104E, 1993
	Rousseau MR, Visser FG, Bax JJ, Dubrey S, Cocco G, Pouleur H, Harris SA, Wolff AA. Ranolazine: anti-anginal therapy with a novel mechanism: placebo controlled comparison versus atenolol. Eur Heart J 15 (Suppl I):95, 1994.
	Rousseau MR, Visser FG, Bax JJ, Noble MIM, Dubrey S, Cocco G, Pasteuning WH, Williams G, Dodds P, Pouleur H. Is modulation of myocardial metabolism as effective as $\beta$ -blockade in exercise-induced angina? J Am Coll Cardiol 23 (Supp I):268A, 1994
KG	Smith WB, Chrysant S, Garland WT, Parker TS, Walpole HT, Mokatrin A, Gennevois D, Pepine CJ. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. J Am Coll Cardio 24A, February 1995
EXAMINER	DATE CONSIDERED
	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. D partment of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  98,164-H23	<b>Serial No.</b>  To Be Assigned
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b>  Wolff et al.	
		<b>Filing Date:</b>  Currently Herewith	<b>Group:</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**


KG		McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. Am Physiol Society, 905-910, 1996.
		Wang JX, et al., "Antianginal effects of ranolazine in various experimental models of angina." Arzeimittelforschung 1999 Mar; 49(3): 193-9
		Matsumura H., et al. "Protective effects of ranolazine, a novel anti-ischemic drug on the hydrogen peroxide-induced derangements in isolated, perfused rate heart: comparison with dichloroacetate." Jpn J Pharmacol. 1998 May; 77(1):31-9
		McCormack JG, et al., "Ranolazine; a novel metabolic modulator for the treatment of angina." Gen Pharmacol. 1998 May; 30(5): 639-45.
		Bagger JP, et al., "Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease." Cardiovasc Drugs Ther. 1997 Jul;11(3): 479-84.
KG		Aaker A, et al., "Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction." J Cardiovasc Pharmacol. 1996 Sept; 28(3):353-62.

KG		Allely MC, Alps BJ, Kilpatrick AT. The effects of the novel anti-anginal agent RS-43285 on [lactic acid], [K <sup>+</sup> ] and pH in a canine model of transient myocardial ischaemia. Biochemical Society Transactions 622 <sup>nd</sup> Meeting, Leicester 15:1057-1058, 1987
		Alley MC, Alps BJ. The effects of the novel anti-anginal agent ranolazine (I.D.) in a canine model of transient myocardial ischaemia. Br J Pharmacol 93(Suppl):246P, 1988
		Brown CM, Clarke B, Dye A, Fraser S, Kenny BA, Kilpatrick AT, Patmore L, Spedding M, Whiting RL. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia. Br J Pharamacol 93(Suppl):248P, 1988
		Ferrandon P, Pascall JC, Armstrong JM. Protective effects of the novel anti-ischaemic agent ranolazine (RS-43285) in perfused rat hearts. Br J Pharmacol 93(Suppl):247P, 1988
		Pouleur H, Hue L, Harlo BJ, Rousseau MF. Metabolic pathways modulation: a new approach to treat myocardial ischemia? Circulation 80, (Supp II):52, 1989
KG		Ferrandon P, Chaylat C, Armstron JM. Free radical scavengers fail to increase the protective effects of ranolazine in isolated working rat hearts after ischemia and reperfusion. Eur J Pharmacol 183:328-329, 1990
EXAMINER  		DATE CONSIDERED  11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  98,164-H23	<b>Serial No.</b>  To Be Assigned
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b>  Wolff et al.	
		<b>Filing Date:</b> Currently Herewith	<b>Group:</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

KG		Lodge JPA, Lam FT, Perry SL, Giles GR. Ranolazine - a new drug with beneficial effects on renal preservation. Transplantation 50:755-759, 1990.
		Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with $\beta$ -blocker or diltiazem. J Cardiovasc Pharmacol 20:131-138, 1992
		Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of $\alpha_1$ -adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol 21:869-873, 1993
		Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 109:748-750, 1993
		Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 24:921-928, 1994.
		Gralinski MR, Black SC, Kilgor KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovascular Research 28:1231-1237, 1994
		Hayashida W, Eyll CV, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovascular Drugs and Therapy 8:741-747, 1994.
		Thadani U, Exekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90:726-734, 1994
		Herron WJ, Eadie J, Penman AD. Estimation of ranolazine and eleven Phase I metabolites in human plasma by liquid chromatography - atmospheric pressure chemical ionisation mass spectrometry with selected -ion monitoring. Journal of Chromatography A 712:55-60, 1995
		Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Communications in Mass Spectrometry 9:1418-1430, 1995
		Wyatt KM, Skene C, Veitch K, Hue L, McCormack JG. The anti-anginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochemical Pharmacol 50:1599-1606, 1995
		Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 118:249-254, 1996
		Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28:341-350, 1996.
KG		McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135-142, 1996
EXAMINER  		DATE CONSIDERED  4/22/97

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.